Several other equities research analysts have also issued reports on the stock. Oppenheimer increased their price objective on shares of Crispr Therapeutics from $65.00 to $80.00 and gave the stock an “outperform” rating in a research report on Monday, November 25th. Chardan Capital restated a “buy” rating and set a $72.50 target price on shares of Crispr Therapeutics in a report on Monday, November 18th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $104.00 price target on shares of Crispr Therapeutics in a research report on Tuesday, November 26th. ValuEngine upgraded Crispr Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, November 1st. Finally, TheStreet raised Crispr Therapeutics from a “d” rating to a “c” rating in a research report on Monday, October 28th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Crispr Therapeutics currently has an average rating of “Buy” and an average price target of $69.54.
Shares of NASDAQ:CRSP traded up $1.66 during trading on Friday, reaching $72.37. 893,783 shares of the stock were exchanged, compared to its average volume of 703,877. The firm’s 50-day moving average price is $54.81 and its 200 day moving average price is $47.38. The firm has a market cap of $3.95 billion, a price-to-earnings ratio of -21.04 and a beta of 3.30. Crispr Therapeutics has a 12-month low of $22.22 and a 12-month high of $74.00. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32.
Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Monday, October 28th. The company reported $2.40 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. The firm had revenue of $211.93 million for the quarter, compared to analyst estimates of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. As a group, equities research analysts forecast that Crispr Therapeutics will post 0.65 EPS for the current year.
In related news, President Rodger Novak sold 33,618 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the sale, the president now directly owns 33,618 shares of the company’s stock, valued at approximately $2,353,260. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Pablo J. Cagnoni sold 7,500 shares of the business’s stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $52.00, for a total transaction of $390,000.00. Following the sale, the director now owns 7,500 shares of the company’s stock, valued at approximately $390,000. The disclosure for this sale can be found here. Insiders have sold a total of 56,118 shares of company stock worth $3,620,760 over the last 90 days. 21.40% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. NEXT Financial Group Inc grew its holdings in shares of Crispr Therapeutics by 915.0% during the third quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock valued at $25,000 after purchasing an additional 549 shares during the last quarter. Benjamin Edwards Inc. lifted its holdings in shares of Crispr Therapeutics by 96.4% in the 2nd quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock worth $26,000 after purchasing an additional 268 shares during the last quarter. Coastal Investment Advisors Inc. acquired a new position in Crispr Therapeutics during the 3rd quarter valued at approximately $26,000. US Bancorp DE boosted its position in Crispr Therapeutics by 553.7% during the 2nd quarter. US Bancorp DE now owns 621 shares of the company’s stock valued at $29,000 after purchasing an additional 526 shares during the period. Finally, BSW Wealth Partners acquired a new position in Crispr Therapeutics during the 2nd quarter valued at approximately $39,000. 49.81% of the stock is currently owned by hedge funds and other institutional investors.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.